Mga Batayang Estadistika
| LEI | 213800YPP55UMHWA4826 |
| CIK | 1645113 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NovoCure Limited
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 28, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 24, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 24, 2025 |
Novocure Reports Second Quarter 2025 Financial Results Novocure Reports Second Quarter 2025 Financial Results Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 30, 2025 |
As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. |
|
| June 6, 2025 |
2025 NovoCure Limited Employee Share Purchase Plan 2025 NOVOCURE LIMITED EMPLOYEE SHARE PURCHASE PLAN (Effective June 4, 2025) 1.Purpose. The purpose of the 2025 NovoCure Limited Employee Share Purchase Plan (the “Plan”) is to encourage and enable eligible employees of NovoCure Limited (the “Company”) and certain designated affiliated companies to acquire proprietary interests in the Company through the ownership of Ordinary Shares of the Company. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 4, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 2, 2025 |
Exhibit 99.1 Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally |
|
| June 2, 2025 |
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004V2. PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) Vincent Picozzi, Hani Babiker, Sreenivasa Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullo |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 31, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 2, 2025 |
panova-3ascoinvestoreven [Confidential] © 2025 Novocure GmbH© 2025 Novocure GmbH 1 PANOVA-3 Investor Event May 31, 2025 – Chicago Exhibit 99. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 24, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 24, 2025 |
Novocure Reports First Quarter 2025 Financial Results Novocure Reports First Quarter 2025 Financial Results Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure L |
|
| April 24, 2025 |
Employment Agreement between Uri Weinberg and Novocure GmbH effective as of August 1, 2024# |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 22, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 22, 2025 |
Exhibit 99.1 Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark approval is supported by the Phase 3 LUNAR trial which demonstrated the first s |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| February 27, 2025 |
etween Novocure (Israel) Ltd. and Barak Ben-A Exhibit. 10.48 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into in Tel-Aviv, Israel on April 1, 2022 (hereinafter, the “Effective Date”), by and between Novocure (Israel) Ltd., of Topaz Building, 4th floor, MATAM Center, Sha’ar Ha’Carmel, P.O. Box 15022, Haifa 3190500, a company incorporated under the laws of the State of Israel (the “Company”), and Barak Ben-Arye |
|
| February 27, 2025 |
ricted Share Unit Award Notice under 2024 Omnibus Incentive Plan NOVOCURE 2024 OMNIBUS INCENTIVE PLAN FORMS OF RESTRICTED SHARE UNIT AWARD NOTICE Form of USA Grant. |
|
| February 27, 2025 |
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limite |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 27, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 27, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NovoCure Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Rule 457(c) and Rule 457(h) 2,085,261 $20. |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 10.49 NOVOCURE 2024 OMNIBUS INCENTIVE PLAN FORMS OF SHARE OPTION AGREEMENT Form of USA Grant................................................................................................. 2 Form of ISL Grant................................................................................................... 7 Form of Swiss Grant.............................................................. |
|
| February 27, 2025 |
SUBSIDIARIES OF NOVOCURE LIMITED Exhibit 21 SUBSIDIARIES OF NOVOCURE LIMITED Name of Subsidiary and Name Under Which It Does Business Jurisdiction of Incorporation Novocure Austria GmbH Austria Novocure Belgium S. |
|
| February 27, 2025 |
024 Omnibus Incentive Plan - Swiss Sub Plan# 1 Exhibit 10.9 NOVOCURE LIMITED 2024 OMNIBUS INCENTIVE PLAN SUB-PLAN FOR SWITZERLAND This Sub-Plan (“Sub-Plan”) to the Novocure Limited 2024 Omnibus Incentive Plan (the “Plan”) is hereby established effective as of June 5, 2024. 1. Definitions 1.1 For purposes of this Sub-Plan, the following definition shall apply: “Swiss Award Agreement” shall mean any agreement between Company and a Participant |
|
| February 27, 2025 |
NOVOCURE 2024 OMNIBUS INCENTIVE PLAN FORMS OF PERFORMANCE-BASED RESTRICTED SHARE UNIT AWARD NOTICE Form of USA Grant. |
|
| January 13, 2025 |
EXHIBIT 99.1 Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reporte |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 30, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| December 17, 2024 |
Employment Agreement between Ashley Cordova and Novocure GmbH effective as of January 1, 2025 Exhibit 10.1 Chief Executive Officer Employment Agreement By and between Novocure GmbH, D4 Park 6, 6039 Root D4, Switzerland (hereinafter the "Company") and Ashley Cordova, 1550 Liberty Ridge Drive, Suite 115, Wayne PA USA (hereinafter "you") Effective Date: 1 January 2025 The purpose of this employment agreement (the "Agreement") is to set forth and acknowledge the terms of your continued employm |
|
| December 17, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is entered into in Tel-Aviv, Israel effective as of January 1, 2025 (hereinafter, the “Effective Date”), by and between Novocure (Israel) Ltd., of Topaz Building, 4th floor, MATAM Center, Sha’ar Ha’Carmel, P.O. Box 15022, Haifa 3190500, a company incorporated under the laws of t |
|
| December 2, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 2, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 2, 2024 |
EX-99.1 2 specialreportdec2024pr.htm EX-99.1 Exhibit 99.1 Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first- |
|
| October 30, 2024 |
Exhibit 10.1 Chief Financial Officer Employment Agreement By and between Novocure GmbH, D4 Park 6, 6039 Root D4, Switzerland (hereinafter the "Company") and Christoph Brackmann, Sonnenbergstrasse 119, 8032 Zurich, Switzerland (hereinafter "you") Effective Date: 1 January 2025 The purpose of this employment agreement (the "Agreement") is to set forth and acknowledge the terms of your continued empl |
|
| October 30, 2024 |
Novocure Reports Third Quarter 2024 Financial Results Exhibit 99.1 Novocure Reports Third Quarter 2024 Financial Results Quarterly net revenues of $155 million, up 22% year-over-year, with 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cord |
|
| October 30, 2024 |
Novocure Appoints Christoph Brackmann as Chief Financial Officer Exhibit 99.2 Novocure Appoints Christoph Brackmann as Chief Financial Officer ROOT, Switzerland – Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 29, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCu |
|
| October 15, 2024 |
Exhibit 99.1 FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first |
|
| October 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 15, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| September 3, 2024 |
Exhibit 99.1 Novocure Announces Planned CEO Transition After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Root, Switzerland – Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO |
|
| September 3, 2024 |
Exhibit 10.1 October 1, 2024 Mr. Wilhelmus Groenhuysen 1150 Queens Rangers Lane West Chester, PA 19382 USA Dear Wilco: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment relationship will |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 30, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 25, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
As filed with the Securities and Exchange Commission on July 25, 2024 As filed with the Securities and Exchange Commission on July 25, 2024 Registration No. |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| July 25, 2024 |
Novocure Reports Second Quarter 2024 Financial Results Exhibit 99.1 Novocure Reports Second Quarter 2024 Financial Results Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter e |
|
| July 10, 2024 |
NovoCure Limited Le Masurier House La Rue Le Masurier St. Helier, Jersey JE2 4YE July 10, 2024 NovoCure Limited Le Masurier House La Rue Le Masurier St. Helier, Jersey JE2 4YE July 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549 Attention: Tayyaba Shafique Terence O’Brien Re: NovoCure Limited Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 22 |
|
| July 10, 2024 |
NVCR / NovoCure Limited / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Novocure Ltd Title of Class of Securities: Common Stock CUSIP Number: G6674U108 Date of Event Which Requires Filing of this Statement: June 28, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| June 10, 2024 |
NovoCure Limited 2024 Omnibus Incentive Plan NOVOCURE LIMITED 2024 OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE The purpose of this NovoCure Limited 2024 Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its shareholders by enabling the Company to offer Eligible Employees, Consultants and Non‑Employee Directors incentive awards in order to attract, retain and reward such individuals and strengthen the mutuality of interests between such individuals and the Company’s shareholders. |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 5, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 20, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 2, 2024 |
Novocure Reports First Quarter 2024 Financial Results Exhibit 99.1 Novocure Reports First Quarter 2024 Financial Results Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA m |
|
| May 2, 2024 |
Exhibit 10.1 LOAN AGREEMENT Dated as of May 1, 2024 among NOVOCURE LUXEMBOURG (as Borrower, and a Credit Party), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR LIMITED PARTNERSHIP (as a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) TABLE OF CONTENTS Page 1 ACCO |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 2, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure L |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| April 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 27, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 27, 2024 |
Exhibit 99.1 METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patien |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 22, 2024 |
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U. |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 22, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limite |
|
| February 22, 2024 |
SUBSIDIARIES OF NOVOCURE LIMITED Exhibit 21 SUBSIDIARIES OF NOVOCURE LIMITED Name of Subsidiary and Name Under Which It Does Business Jurisdiction of Incorporation Novocure Austria GmbH Austria Novocure Belgium S. |
|
| February 22, 2024 |
imited Policy Statement on Securities Trades by Company Officers, Directors Exhibit 19 NOVOCURE LIMITED POLICY STATEMENT ON SECURITIES TRADES BY COMPANY OFFICERS, DIRECTORS AND EMPLOYEES Introduction In the normal course of business, employees, officers and directors of NovoCure Limited (the “Company”) may use or have access to confidential and material information that is not generally available to the investing public. |
|
| February 22, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NovoCure Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Rule 457(c) and Rule 457(h) 5,347,750 $15. |
|
| February 22, 2024 |
Non-Employee Director Compensation Program Exhibit 10.23 NovoCure Limited Non-Employee Director Compensation Program 1. General. This Non-Employee Director Compensation Program (this “Program”) is adopted by the Board of Directors (the “Board”) of NovoCure Limited, a public limited company incorporated under the laws of Jersey, Channel Islands (the “Company”). For purposes of this Program, a “Non-Employee Director” shall mean a director of |
|
| February 22, 2024 |
Exhibit 97 NOVOCURE LIMITED AMENDED AND RESTATED POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION EFFECTIVE AS OF OCTOBER 2, 2023 The Board of Directors (the “Board”) of NovoCure Limited (“Company”) has adopted this Policy on Recoupment of Incentive Compensation (the “Clawback Policy” or “Policy”) to comply with the rules found in 229 C. |
|
| February 13, 2024 |
NVCR / NovoCure Limited / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01574-novocureltd.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Novocure Ltd Title of Class of Securities: Common Stock CUSIP Number: G6674U108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 9, 2024 |
NVCR / NovoCure Limited / BlackRock Inc. Passive Investment SC 13G/A 1 je00byss4x48020824.txt je00byss4x48020824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) NovoCure Ltd - (Name of Issuer) Common Stock - (Title of Class of Securities) BYSS4X4 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 9, 2024 |
NVCR / NovoCure Limited / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2024 |
NVCR / NovoCure Limited / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 18, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 18, 2024 |
Exhibit 99.1 Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer ROOT, Switzerland – Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), f |
|
| January 9, 2024 |
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma Exhibit 99.2 Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma Final data from the TRIDENT trial anticipated in 2026 ROOT, Switzerland – Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®) |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 9, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 8, 2024 |
Exhibit 99.1 Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D. appointed as Novocure Chief Medical Officer, effective Janua |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 4, 2024 |
Employment Agreement, dated as of Exhibit 10.1 January 4, 2024 Mr. Frank Leonard Novocure USA LLC 1550 Liberty Ridge Drive, Suite 115 Wayne, Pennsylvania 19087 Dear Frank: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employmen |
|
| January 4, 2024 |
, between Novocure USA LLC and Pritesh Shah# Exhibit 10.2 January 4, 2024 Mr. Pritesh Shah Novocure USA LLC 1500 Broadway, 17th Floor New York, NY 10036 Dear Pritesh: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment relationship w |
|
| January 4, 2024 |
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer Exhibit 99.1 Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer ROOT, Switzerland – Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncol |
|
| December 11, 2023 |
NVCR / NovoCure Ltd / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 28, 2023 |
Exhibit 99.1 Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating expenses of approximately $60 million |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 28, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCu |
|
| October 26, 2023 |
Novocure Reports Third Quarter 2023 Financial Results Exhibit 99.1 Novocure Reports Third Quarter 2023 Financial Results Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 26, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 28, 2023 |
Exhibit 99.1 Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer ROOT, Switzerland – Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 28, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| July 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 27, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 27, 2023 |
Novocure Reports Second Quarter 2023 Financial Results Exhibit 99.1 Novocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024 Interim analysis for fully enrolled phase 3 PANOVA-3 trial in pancreatic c |
|
| July 21, 2023 |
EXHIBIT 99.1 Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned Root, Switzerland – Novocure (NASDAQ: NVCR) today announced the results of |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 21, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 7, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2023 |
Exhibit 99.1 LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versu |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 6, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 6, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2023 |
ascoinvestorslides PRESENTED BY: Tumor Treating Fields (TTFields) Therapy with Standard of Care (SOC) in Metastatic Non-Small Cell Lung Cancer (mNSCLC) After Platinum-based Therapies: Randomized, Phase 3 LUNAR Study Ticiana Leal, MD, Winship Cancer Institute - Emory University Ticiana Leal1, Rupesh Kotecha2, Rodryg Ramlau3, Li Zhang4, Janusz Milanowski5, Manuel Cobo6, Jaromir Roubec7, Lubos Petruzelka8, Libor Havel9, Sujith Kalmadi10, Jeffrey Ward11, Zoran Andric12, Thierry Berghmans13, David E. |
|
| June 6, 2023 |
ascoinvestorslide-mnpi ✓ |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 6, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 6, 2023 |
• • • • • α • • • • • • • • • • • • • − − • • • • • • • • • ascolunarstudyresultssli • • • • • α • • • • • • • • • • • • • − − • • • • • • • • • |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure L |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 4, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 4, 2023 |
Employment Agreement, dated as of May 3, 2023, by and between NovoCure USA LLC and Francis Leonard Ex. 10.1 May 3, 2023 Mr. Frank Leonard Novocure USA LLC 1550 Liberty Ridge Drive, Suite 115 Wayne, Pennsylvania 19087 Dear Frank: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment relati |
|
| May 4, 2023 |
Novocure Reports First Quarter 2023 Financial Results Exhibit 99.1 Novocure Reports First Quarter 2023 Financial Results Data from phase 3 LUNAR clinical trial in non-small cell lung cancer to be presented June 6th at ASCO Annual Meeting Enrollment of phase 3 METIS clinical trial completed, the fourth phase 3 clinical trial to complete enrollment in last 18 months Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the qu |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 26, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 26, 2023 |
Exhibit 99.1 Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Root, Switzerland – Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 Ame |
|
| April 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| April 24, 2023 |
DEFA14A 1 defa-14a2023proxynotice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 28, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 29, 2023 |
Kristin Stafford Joins Novocure Board of Directors Exhibit 99.1 Kristin Stafford Joins Novocure Board of Directors Root, Switzerland – Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience with a |
|
| February 23, 2023 |
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of the pivotal PANOVA-3 study in pancreatic cancer ROOT, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limite |
|
| February 23, 2023 |
SUBSIDIARIES OF NOVOCURE LIMITED Exhibit 21 SUBSIDIARIES OF NOVOCURE LIMITED Name of Subsidiary and Name Under Which It Does Business Jurisdiction of Incorporation Novocure Austria GmbH Austria Novocure Canada, Inc. |
|
| February 23, 2023 |
Exhibit 4.1 NOVOCURE LIMITED DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NovoCure Limited, a Jersey corporation (“we,” “us” or “our”) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934: our ordinary shares, no par value per share. Our ordinary shares are listed on the NASDAQ Global Select Marke |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NovoCure Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Rule 457(c) and Rule 457(h) 4,200,374 $82. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 23, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 13, 2023 |
NVCR / Novocure Ltd / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 13, 2023 |
NVCR / Novocure Ltd / Capital International Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2023 |
NVCR / Novocure Ltd / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01541-novocureltd.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Novocure Ltd. Title of Class of Securities: Common Stock CUSIP Number: G6674U108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| January 31, 2023 |
NVCR / Novocure Ltd / BlackRock Inc. Passive Investment SC 13G/A 1 je00byss4x48013123.txt je00byss4x48013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) NovoCure Ltd - (Name of Issuer) Common Stock - (Title of Class of Securities) BYSS4X4 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 9, 2023 |
Exhibit 99.1 Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients t |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 9, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| January 5, 2023 |
Exhibit 99.1 Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress ROOT, Switzerland – Novocure (NASDAQ: NVCR) today announced the LUNAR s |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 5, 2023 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Comm |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 27, 2022 |
Novocure Reports Third Quarter 2022 Financial Results Exhibit 99.1 Novocure Reports Third Quarter 2022 Financial Results Quarterly net revenues of $131 million with $52 million invested in research & development initiatives Entering a transformational period with multiple pivotal trial readouts anticipated in coming quarters Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCu |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 27, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 28, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 28, 2022 |
Non-Employee Director Compensation Program Exhibit 10.2 Non-Employee Director Compensation Program 1. General. This Non-Employee Director Compensation Program (this ?Program?) is adopted by the Board of Directors (the ?Board?) of NovoCure Limited, a public limited company incorporated under the laws of Jersey, Channel Islands (the ?Company?). For purposes of this Program, a ?Non-Employee Director? shall mean a director of the Company who i |
|
| July 28, 2022 |
Novocure Reports Second Quarter 2022 Financial Results Exhibit 99.1 Novocure Reports Second Quarter 2022 Financial Results Quarterly net revenues of $140.9 million, a 6% increase year-over-year Root, Switzerland ? Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing i |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 8, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 10, 2022 |
Amended and Restated Articles of Association of NovoCure Limited Exhibit 3.1 COMPANIES (JERSEY) LAW 1991 ARTICLES OF ASSOCIATION OF NOVOCURE LIMITED a no par value public limited company Company number: 76264 Adopted by special resolution on the 8th day of June, 2022 Exhibit 3.1 COMPANIES (JERSEY) LAW 1991 ARTICLES OF ASSOCIATION OF NOVOCURE LIMITED a no par value public limited company CONTENTS 1. INTERPRETATION................................................. |
|
| June 3, 2022 |
Exhibit 99.1 Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% ST. |
|
| June 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 3, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 26, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 20, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 26, 2022 |
EXHIBIT 99.1 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA? (pembrolizumab) in Newly Diagnosed Glioblastoma ST. HELIER, Jersey ? Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the u |
|
| May 26, 2022 |
2022 by and among Novocure GmbH, Merck International GmbH and MSD International Business GmbH Exhibit 10.1 Execution Version CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between MSD International GmbH, MSD International Business GmbH, and Novocure GmbH Dated: May 18, 2022 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMITTED INFORMATION |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 28, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 28, 2022 |
Novocure Reports First Quarter 2022 Financial Results Exhibit 99.1 Novocure Reports First Quarter 2022 Financial Results Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term St. Helier, Jersey ? Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a global oncology company working to extend survival |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure L |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 11, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 1, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 7, 2022 |
Employment Agreement, dated as of April 1, 2022, by and between NovoCure USA LLC and Todd Longsworth EXHIBIT 10.1 April 1, 2022 Mr. Todd Longsworth Novocure USA LLC 195 Commerce Way Portsmouth, NH 03801 Dear Todd: The purpose of this letter (this ?Agreement?) is to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment relationship will continue to be with Novocure USA LLC, a Delaware limited liability company (the ?Company?) and a who |
|
| March 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 23, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 23, 2022 |
EXHIBIT 99.1 Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned St. Helier, Jersey ? Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVAT |
|
| February 24, 2022 |
Amendment No. 1 dated as of December 6, 2021 to Credit Agreement dated as of November 6, 2020 ex10432021am1tocreditagr US-DOCS\126633438.3 EXECUTION COPY AMENDMENT NO. 1 Dated as of December 6, 2021 to CREDIT AGREEMENT Dated as of November 6, 2020 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of December 6, 2021 by and between NovoCure Limited, a public company incorporated in Jersey, Channel Islands (registered number 76264) (the “Company”), and JPMorgan Chase Bank, N.A., as Administ |
|
| February 24, 2022 |
SUBSIDIARIES OF NOVOCURE LIMITED Exhibit 21 SUBSIDIARIES OF NOVOCURE LIMITED Name of Subsidiary and Name Under Which It Does Business Jurisdiction of Incorporation Novocure Austria GmbH Austria Novocure Canada, Inc. |
|
| February 24, 2022 |
Exhibit 10.41 PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (this "Agreement") is made this 1st day of December, 2021 by and between 64 Vaughan Mall, LLC, a New Hampshire limited liability company with an address of 41 Industrial Drive, Unit 20, Exeter, New Hampshire 03833 (the ?Seller?), and Novocure Inc., a Delaware corporation, having an address of 195 Commerce Way, Portsmouth, N |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limite |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 24, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 24, 2022 |
Calculation of Filing Fee Table* Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NovoCure Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Rule 457(c) and Rule 457(h) 4,157,284 $77. |
|
| February 24, 2022 |
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology St. |
|
| February 24, 2022 |
Exhibit 10.42 CERTAIN IDENTIFIED SCHEDULES AND EXHIBITS HAVE BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED SCHEDULES AND EXHIBITS MARKED WITH ASTERISKS AGREEMENT made as of the ? 30 ? day of ? December ? in the year ? 2021 ? (In words, indicate day, month and year.) BETWEEN the Owner: (Name, legal status, a |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 11, 2022 |
NVCR / Novocure Ltd / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
NVCR / Novocure Ltd / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 10, 2022 |
NVCR / Novocure Ltd / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01543-novocureltd.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Novocure Ltd. Title of Class of Securities: Common Stock CUSIP Number: G6674U108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule |
|
| January 10, 2022 |
Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update Preliminary full year 2021 net revenues of $535 million and fourth quarter net revenues of $133 million DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated in early Q2 2022 given limited number of events to date in fast-recruiting trial Novocure to present at the 40th Annual J. |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 30, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| December 7, 2021 |
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire The property will provide space for Novocure?s growing workforce, and house a world-class training and development center St. |
|
| December 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 7, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCu |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 28, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 28, 2021 |
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $133. |
|
| August 10, 2021 |
NVCR / Novocure Ltd / Capital International Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 29, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 29, 2021 |
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $133. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 9, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) April 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 29, 2021 |
February 3, 2017 Mr. Todd Longsworth 132 Trianon Lane Villanova, PA 19085 NOVOCURE LLC 195 Commerce Way Portsmouth, NH 03801 EMPLOYEE AGREEMENT Dear Todd: The purposes of this letter (this "Agreement") are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your |
|
| April 29, 2021 |
Non-Employee Director Compensation Program# Non-Employee Director Compensation Program 1. General. This Non-Employee Director Compensation Program (this ?Program?) is adopted by the Board of Directors (the ?Board?) of NovoCure Limited, a public limited company incorporated under the laws of Jersey, Channel Islands (the ?Company?). For purposes of this Program, a ?Non-Employee Director? shall mean a director of the Company who is not an empl |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure L |
|
| April 29, 2021 |
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update Novocure Reports First Quarter 2021 Financial Results and Provides Company Update Quarterly net revenues of $134. |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2021 |
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial St. |
|
| April 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 13, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Commi |
|
| February 25, 2021 |
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update Quarterly net revenues of $144. |
|
| February 25, 2021 |
SUBSIDIARIES OF NOVOCURE LIMITED Exhibit 21 SUBSIDIARIES OF NOVOCURE LIMITED Name of Subsidiary and Name Under Which It Does Business Jurisdiction of Incorporation Novocure Austria GmbH Austria Novocure Canada, Inc. |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
February 24, 2021 Mr. William F. Doyle c/o Novocure USA LLC 195 Commerce Way Portsmouth, New Hampshire 03801 Dear Mr. Doyle: The purpose of this letter amendment (this ?Amendment?) is to amend certain terms set forth the letter agreement dated as of May 16, 2016 (the ?Agreement?) between you and Novocure USA LLC, a Delaware limited liability company (the ?Company?) regarding your employment with t |
|
| February 25, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 25, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limite |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NovoCure Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G6674U108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Novocure Ltd. Title of Class of Securities: Common Stock CUSIP Number: G6674U108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 5, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| February 8, 2021 |
Novocure Announces Addition to Its Board of Directors Novocure Announces Addition to Its Board of Directors Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, elected to board of directors St. Helier, Jersey – Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on February 5, 2021. “We are extremely pleased to |
|
| February 1, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 1, 2021 |
NOTICE OF IRREVOCABLE ELECTION TO SETTLE CONVERSIONS OF ALL NOTES WITH COMBINATION SETTLEMENT AND A SPECIFIED DOLLAR AMOUNT OF $1,000 NOVOCURE LIMITED 0% Convertible Senior Notes due 2025 Aggregate Principal Amount: $575,000,000 Maturity Date: November 1, 2025 CUSIP: 67011X AA1 ISIN: US67011XAA19 NOTICE IS HEREBY GIVEN, pursuant to Section 14. |
|
| February 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 29, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 11, 2021 |
Three months ended December 31, Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update Full year 2020 preliminary net revenues of $494. |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 11, 2021 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 21, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-1(a) (Amendment No. 1) NovoCure Limited (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) G6674U 108 (CUSIP Number) Andrew Abram |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 6, 2020 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 9, 2020 |
novocure-2020creditagree EXECUTION COPY CREDIT AGREEMENT dated as of November 6, 2020 among NOVOCURE LIMITED The Subsidiary Borrowers Party Hereto The Lenders Party Hereto and JPMORGAN CHASE BANK, N. |
|
| November 9, 2020 |
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks Provides flexible capital structure prior to anticipated period of significant innovation and growth St. |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 5, 2020 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 5, 2020 |
Indenture, dated November 5, 2020, between NovoCure Limited. and U.S. Bank National Association EXECUTION VERSION NOVOCURE LIMITED AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 5, 2020 0% Convertible Senior Notes due 2025 #93753236v10 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions 1 Section 1.02 . References to Interest 13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01 . Designation and Amount |
|
| November 5, 2020 |
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement Initial conversion price represents a premium of approximately 50% St. |
|
| November 3, 2020 |
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes St. |
|
| November 3, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 2, 2020 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 3, 2020 |
Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement Initial conversion price represents a premium of approximately 50% St. |
|
| October 29, 2020 |
Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update EX-99.1 2 nvcr-20200930xpr.htm EX-99.1 Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share St. Helier, Jersey – Novocure (NASDAQ: NVCR) today re |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCu |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 October 29, 2020 Date of Report (date of earliest event reported) NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| October 2, 2020 |
CORRESP 57 filename57.htm NovoCure Limited No. 4 The Forum Grenville Street St. Helier, Jersey JE2 4UF October 2, 2020 VIA EDGAR Eric Atallah Kevin J. Kuhar Accounting Branch Chief U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, DC 20549 Re: NovoCure Limited Form 10-K for the Fiscal Year Ended December 31, 2019 Filed February 27, 2020 For |
|
| August 13, 2020 |
EXHIBIT 10.3 September 1, 2020 Mr. Michael J. Ambrogi Novocure USA LLC 195 Commerce Way Portsmouth, NH 03801 Dear Michael: The purpose of this letter (this “Agreement”) is to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment relationship will continue to be with Novocure USA LLC, a Delaware limited liability company (the “Company”) |
|
| August 13, 2020 |
EXHIBIT 10.1 September 1, 2020 Mr. Wilhelmus C.M. Groenhuysen Novocure USA LLC 20 Valley Stream Parkway Malvern, PA 19355 Dear Wilco: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal employment re |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 13, 2020 |
EXHIBIT 10.2 September 1, 2020 Ms. Ashley Cordova Novocure USA LLC 20 Valley Stream Parkway, Suite 300 Malvern, Pennsylvania 19355 Dear Ashley: The purposes of this letter (this “Agreement”) are to amend and restate the terms and conditions of your Prior Agreement (as defined below) and to set forth and acknowledge certain terms of your continued employment with the Novocure Group. Your formal emp |
|
| August 13, 2020 |
Confidential | Do Not Distribute Exhibit 99.1 Novocure Announces Expansion of its Executive Leadership Team Wilco Groenhuysen appointed to an expanded Chief Operating Officer role Ashley Cordova promoted to Chief Financial Officer Frank Leonard promoted to Chief Development Officer St. Helier, Jersey – Novocure (NASDAQ: NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to furth |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 NovoCure Limited (Exact name of registrant as specified in its charter) Jersey 001-37565 98-1057807 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Li |
|
| July 30, 2020 |
EX-99.1 2 nvcr2020q2earningsrele.htm EX-99.1 Exhibit 99.1 Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update Quarterly net revenues of $115.9 million, representing 34 percent growth versus the second quarter 2019 and 14 percent growth versus the first quarter 2020 Financial strength allows for continued investments in clinical and product innovation St. Helier, Jers |
